Latest Research And Development News

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

CurveBeam AI Limited has secured A$6.5 million in new capital to fuel global growth of its HiRise™ weight-bearing CT scanner, deepen its partnership with orthopaedic giant Stryker, and advance a potential strategic deal in China.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.

HITIQ Ltd has raised $250,000 through a premium-priced placement and secured a $1.4 million RDTI loan facility to support its pivot towards consumer concussion management technology.

Firebird Metals has raised A$6 million through a placement led by top-tier institutions and directors, aiming to fast-track its manganese-rich cathode technology and expand R&D capabilities in Australia and China.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Noxopharm Limited has secured an extension on $2.6 million of convertible notes and obtained a $1.25 million unsecured loan to bolster working capital, pending shareholder approval.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

Swift Networks secures a landmark Master Services Agreement with Opal HealthCare to deploy its innovative Swift TV platform across multiple aged care communities, marking a significant step in aged care technology integration.